Ontrak Announces 2023 Second Quarter Financial Results
Q2 Revenue of $3.0 million and Year to Date Revenue of $5.5 million
Company announces signing of new customer agreement with a regional Medicaid health plan
Company completes reverse stock split of its common stock at a ratio of 1:6
Company announces achievement of certification as a Credentials Verification Organization (CVO) by the National Committee for Quality Assurance (NCQA)
HENDERSON, Nev., August 09, 2023--(BUSINESS WIRE)--Ontrak, Inc. (NASDAQ: OTRK) ("Ontrak" or the "Company"), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the second quarter ended June 30, 2023.
Management Commentary
"We are encouraged by our new customer agreement and other positive developments in our pipeline, which we believe validate our go-to-market strategy that positions us for a return to growth," said Brandon LaVerne, the Company’s Chief Executive Officer and Chief Operating Officer. "Our suite of customized solutions provides our customers and prospects flexible options for engaging their members in need of our support and furthers our mission to help improve the health and save the lives of as many people as possible. We remain focused on delivering innovative behavioral health care solutions, improved clinical outcomes, and tangible cost savings to our customers."
Second Quarter 2023 Financial Results Highlights
All common share and per share amounts presented herein for all periods have been retroactively adjusted to reflect the impact of the reverse stock split (see below for more information).
Revenue for the second quarter of 2023 was $3.0 million, representing a 24% decrease compared to the same period in 2022.
Operating loss for the second quarter of 2023 was $(4.6) million compared to an operating loss of $(11.9) million for the same period in 2022.
Adjusted EBITDA for the second quarter of 2023 was $(3.1) million compared to adjusted EBITDA of $(8.6) million for the same period in 2022.
Net loss for second quarter of 2023 was $(6.8) million, or a $(1.84) diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to net loss of $(15.1) million, or a $(4.97) diluted net loss per common share (after deduction for undeclared preferred stock dividends) for the same period in 2022.
Non-GAAP net loss for second quarter of 2023 was $(5.9) million, or a $(1.66) non-GAAP diluted net loss per common share (after deduction for undeclared preferred stock dividends), compared to non-GAAP net loss of $(10.9) million, or a $(3.78) non-GAAP diluted net loss per common share (after deduction for undeclared preferred stock dividends) for the same period in 2022.
Adjusted EBITDA, non-GAAP net loss and non-GAAP diluted net loss per common share are non-GAAP financial measures. See our description and reconciliation of such non-GAAP measures at the end of this release.
Second Quarter 2023 and Recent Operating Highlights
In July 2023, the Company entered into an agreement with a regional Medicaid health plan for our WholeHealth+ and Ontrak Engage solutions. The agreement is pending state approval and is expected to launch in the fourth quarter of 2023. Total enrolled members in our WholeHealth+ program numbered 1,889 at the end of Q2 2023, compared to 1,526 at the end of Q1 2023 and 2,094 at the end of Q2 2022. On June 23, 2023, the Company and Acuitas Capital, LLC ("Acuitas"), an entity indirectly wholly owned and controlled by Terren S. Peizer, the Company’s largest stockholder and former Chief Executive Officer and Chairman, entered into a Fourth Amendment to the Master Note Purchase Agreement entered into between the Company and Acuitas in April 2022 (the "Fourth Amendment," and as amended to date, the "Keep Well Agreement"), pursuant to which, among other things: a) the Funding Structure was changed to provide the terms for the remaining $6.0 million to be funded thereunder as follows: $4.0 million was to be funded on June 1, 2023 and $2.0 million was to be funded on September 1, 2023. Under the Fourth Amendment, in lieu of the $6.0 million being funded as described above, Acuitas agreed to deliver to the Company for deposit by the Company into a segregated account established by the Company (the proceeds so deposited, the "Escrowed Funds" and the account into which the proceeds are so deposited, the "Escrow Account"): (i) $4.0 million on June 23, 2023 (deposit received by Company on June 26, 2023); and (ii) $2.0 million on September 1, 2023; and b) the maturity date of the Keep Well Notes was extended from June 30, 2024 to September 30, 2024.
On July 27, 2023 (the "Effective Date"), the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware implementing a reverse split at ratio of 1:6. Any fractional share of our common stock resulting from the reverse split was automatically rounded up to the nearest whole share. The Company's common stock began trading on the NASDAQ Capital Market on a post-split basis at the open of trading on July 28, 2023, and continues to trade under the symbol "OTRK," but has been assigned a new CUSIP number (683373302).
The Company announced a breakthrough increase in behavioral health diagnosis, with 42% of members diagnosed with Substance Use Disorder, 27% of members diagnosed with Depression, 27% of members diagnosed with Bipolar Disorder, 21% of members diagnosed with Anxiety and 20% of members diagnosed with Schizophrenia did not have their respective diagnosis prior to enrollment in Ontrak’s WholeHealth+ program.
The Company achieved certification as a CVO by the NCQA for the element of license to practice. This certification further validates Ontrak's commitment to maintaining the highest standards of quality and compliance in its suite of health care solutions, enabling its customers and prospects to effectively meet their accreditation goals.
Financial Outlook
The following outlook is based on information available as of the date of this press release and is subject to change in the future.
For the year ending December 31, 2023, the Company reaffirms its estimate of revenue in the range of $12 to $14 million. The foregoing estimate is based on existing and currently planned enrollment launches, currently anticipated program expansions with current health plan partners, current expectations with the Company’s existing customers regarding outreach pool, budget considerations and timing of expansions.
Conference Call & Webcast Details
The Company will host a conference call/webcast today at 4:30 pm ET/1:30 pm PT. Investors, analysts, employees and the general public can access the call by registering online for dial-in information or via live audio webcast at: https://ontrakhealth.com/investors/presentations-events. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Ontrak, Inc.
Ontrak, Inc. is a leading AI and telehealth-enabled healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. Ontrak identifies, engages, activates and provides care pathways to treatment for the most vulnerable members of the behavioral health population who would otherwise fall through the cracks of the healthcare system. We engage individuals with anxiety, depression, substance use disorder and chronic disease through personalized care coaching and customized care pathways that help them receive the treatment and advocacy they need, despite the socio-economic, medical and health system barriers that exacerbate the severity of their comorbid illnesses. The company’s integrated intervention platform uses AI, predictive analytics and digital interfaces combined with dozens of care coach engagements to deliver improved member health, better healthcare system utilization, and durable outcomes and savings to healthcare payors.
Learn more at www.ontrakhealth.com
Forward-Looking Statements
This press release contains "forward-looking" statements that are based on the Company’s beliefs and assumptions and on information currently available to the Company on the date of this press release and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "may," "will," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plan," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words. Forward-looking statements may include, but are not limited to, the expectations around state approval and timing of launch of the new customer contract, the Company’s belief that its strategy will accelerate the Company’s return to growth, maximize the Company’s differentiated platform, and strengthen the Company’s position, the Company’s expectations regarding reductions in costs resulting from its cost saving measures, and the Company’s estimated revenue for 2023. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements, including, without limitation, risks related to: the Company’s ability to successfully execute on its strategy and business plan; the Company’s ability to increase its revenue and efficiently manage expenses and achieve profitability; the Company’s high customer concentration and the ability of its customers to terminate their contracts for convenience; the adequacy of the Company’s existing cash resources and anticipated capital commitments and future cash requirements to enable the Company to continue as a going concern; the Company’s ability to raise additional capital when needed; difficulty enrolling new members and maintaining existing members in the Company’s programs; the effectiveness of the Company’s treatment programs; lower than anticipated eligible members under the Company’s contracts; the Company’s dependence on key personnel and the Company’s ability to recruit and retain key personnel; the Company’s ability to maintain the listing of its stock on Nasdaq; the outcomes of ongoing legal proceedings brought by the U.S. Department of Justice and the Securities and Exchange Commission against the Company’s largest stockholder and former Chief Executive Officer and Chairman, and whether governmental authorities will institute separate investigations or proceedings against the Company and/or its current or former executives and/or directors; substantial regulation in the health care industry; changes in regulations or issuance of new regulations or interpretations; the Company’s limited operating history; difficulty in developing, exploiting and protecting proprietary technologies; business disruption and related risks resulting from the COVID-19; general economic conditions, nationally and globally, and their effect on the market for our service; intense competition and competitive pressures and trends in the Company’s industry and the Company’s ability to successfully compete; changes in laws, regulations, or policies; and risks related to the Company’s ability to realize the potential benefits of and to effectively integrate acquisitions. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Securities and Exchange Commission filings which are available on its website at http://www.sec.gov. Forward-looking statements are current only as of the date they are made and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Non-GAAP Financial Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles, or GAAP, the Company has provided in this press release and the quarterly conference call held on the date hereof certain non-GAAP financial measures. The non-GAAP financial measures presented include EBITDA, Adjusted EBITDA, Non-GAAP net loss, and Non-GAAP net loss per common share, which are not U.S. GAAP financial measures. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
EBITDA consists of net loss before interest, taxes, depreciation and amortization expenses. Adjusted EBITDA consists of net loss before interest, taxes, depreciation, amortization, stock-based compensation, write-off of debt issuance costs, restructuring, severance and related costs, gain on termination of operating lease, and gain/loss on change in fair value of warrant liability. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.
Non-GAAP net loss consists of net loss adjusted for stock-based compensation, write-off of debt issuance costs, restructuring, severance and related costs, gain on termination of operating lease and gain/loss on change in fair value of warrant liability. Non-GAAP net loss per common share consists of loss per share adjusted for non-GAAP net loss attributable to common stockholders. We believe that making such adjustments provides investors meaningful information to understand our results of operations and the ability to analyze our financial and business trends on a period-to-period basis.
We believe the above non-GAAP financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the term EBITDA, Adjusted EBITDA, Non-GAAP net loss and Non-GAAP net loss per common share may vary from that of others in our industry. None of EBITDA, Adjusted EBITDA, Non-GAAP net loss or Non-GAAP net loss per common share should be considered as an alternative to net loss before taxes, net loss, net loss per common share or any other performance measures derived in accordance with U.S. GAAP as measures of performance.
See the Reconciliation of Non-GAAP Measures table at the end of this press release for a reconciliation of the Non-GAAP financial measures to U.S. GAAP financial measures.
ONTRAK, INC. | |||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Revenue | $ | 2,960 | $ | 3,903 | $ | 5,489 | $ | 9,161 | |||||||
Cost of revenue | 804 | 2,206 | 1,651 | 5,052 | |||||||||||
Gross profit | 2,156 | 1,697 | 3,838 | 4,109 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 1,537 | 2,852 | 3,181 | 6,280 | |||||||||||
Sales and marketing | 837 | 1,306 | 1,827 | 2,742 | |||||||||||
General and administrative | 4,410 | 9,449 | 10,228 | 20,142 | |||||||||||
Restructuring, severance and related charges | — | — | 457 | — | |||||||||||
Total operating expenses | 6,784 | 13,607 | 15,693 | 29,164 | |||||||||||
Operating loss | (4,628 | ) | (11,910 | ) | (11,855 | ) | (25,055 | ) | |||||||
Other (expense) income, net | (5 | ) | (1,972 | ) | 286 | (1,972 | ) | ||||||||
Interest expense, net | (2,223 | ) | (1,156 | ) | (3,617 | ) | (2,556 | ) | |||||||
Loss before income taxes | (6,856 | ) | (15,038 | ) | (15,186 | ) | (29,583 | ) | |||||||
Income tax benefit (expense) | 100 | (20 | ) | 80 | (120 | ) | |||||||||
Net loss | (6,756 | ) | (15,058 | ) | (15,106 | ) | (29,703 | ) | |||||||
Dividends on preferred stock - declared and undeclared | (2,238 | ) | (2,238 | ) | (4,477 | ) | (4,477 | ) | |||||||
Net loss attributable to common stockholders | $ | (8,994 | ) | $ | (17,296 | ) | $ | (19,583 | ) | $ | (34,180 | ) | |||
Net loss per common share, basic and diluted | $ | (1.84 | ) | $ | (4.97 | ) | $ | (4.09 | ) | $ | (9.86 | ) | |||
Weighted-average common shares outstanding, basic and diluted | 4,887 | 3,481 | 4,787 | 3,467 | |||||||||||
ONTRAK, INC. | |||||||
June 30, | December 31, | ||||||
Assets | (unaudited) | ||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 6,094 | $ | 5,032 | |||
Restricted cash - current | 4,000 | 4,477 | |||||
Receivables, net | 282 | 973 | |||||
Unbilled receivables | 364 | 453 | |||||
Deferred costs - current | 188 | 156 | |||||
Prepaid expenses and other current assets | 2,925 | 3,168 | |||||
Total current assets | 13,853 | 14,259 | |||||
Long-term assets: | |||||||
Property and equipment, net | 2,003 | 2,498 | |||||
Restricted cash - long-term | — | 204 | |||||
Goodwill | 5,713 | 5,713 | |||||
Intangible assets, net | 515 | 1,125 | |||||
Other assets | 310 | 1,326 | |||||
Operating lease right-of-use assets | 216 | 632 | |||||
Total assets | $ | 22,610 | $ | 25,757 | |||
Liabilities and stockholders' equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,590 | $ | 1,927 | |||
Accrued compensation and benefits | 681 | 1,987 | |||||
Deferred revenue | 308 | 326 | |||||
Current portion of operating lease liabilities | 50 | 653 | |||||
Other accrued liabilities | 7,116 | 4,576 | |||||
Total current liabilities | 9,745 | 9,469 | |||||
Long-term liabilities: | |||||||
Long-term debt, net | 11,913 | 10,065 | |||||
Long-term operating lease liabilities | 196 | 546 | |||||
Total liabilities | 21,854 | 20,080 | |||||
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; 3,770,265 shares issued and outstanding at each of June 30, 2023 and December 31, 2022 | — | — | |||||
Common stock, $0.0001 par value, 500,000,000 shares authorized; 4,887,874 and 4,527,913 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 3 | 3 | |||||
Additional paid-in capital | 458,600 | 448,415 | |||||
Accumulated deficit | (457,847 | ) | (442,741 | ) | |||
Total stockholders' equity | 756 | 5,677 | |||||
Total liabilities and stockholders' equity | $ | 22,610 | $ | 25,757 | |||
ONTRAK, INC. | |||||||
For the Six Months Ended | |||||||
2023 | 2022 | ||||||
Cash flows from operating activities | |||||||
Net loss | $ | (15,106 | ) | $ | (29,703 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Stock-based compensation expense | 1,543 | 5,063 | |||||
Write-off of debt issuance costs | — | 2,023 | |||||
Paid-in-kind interest expense | 1,936 | — | |||||
Gain on termination of operating lease | (471 | ) | — | ||||
Depreciation expense | 590 | 1,424 | |||||
Amortization expense | 2,382 | 1,310 | |||||
Change in fair value of warrant liability | 12 | (51 | ) | ||||
401(k) employer match in common shares | — | 363 | |||||
Common stock issued for consulting services | — | 102 | |||||
Changes in operating assets and liabilities: | |||||||
Receivables | 691 | 2,340 | |||||
Unbilled receivables | 89 | 2,484 | |||||
Prepaid expenses and other current assets | 326 | 2,136 | |||||
Accounts payable | (371 | ) | 442 | ||||
Deferred revenue | (18 | ) | (119 | ) | |||
Leases liabilities | (142 | ) | (12 | ) | |||
Other accrued liabilities | (1,529 | ) | (2,017 | ) | |||
Net cash used in operating activities | (10,068 | ) | (14,215 | ) | |||
Cash flows from investing activities | |||||||
Purchase of property and equipment | (123 | ) | (754 | ) | |||
Net cash used in investing activities | (123 | ) | (754 | ) | |||
Cash flows from financing activities | |||||||
Proceeds from Keep Well Notes | 8,000 | — | |||||
Proceeds from Keep Well Agreement held in escrow | 4,000 | — | |||||
Dividends paid | — | (2,239 | ) | ||||
Repayments of 2024 Notes | — | (31,694 | ) | ||||
Debt issuance costs | (98 | ) | (440 | ) | |||
Finance lease obligations | (100 | ) | (162 | ) | |||
Financed insurance premium payments | (1,229 | ) | (1,505 | ) | |||
Payment of taxes related to net-settled stock awards | (1 | ) | (3 | ) | |||
Net cash provided by (used in) financing activities | 10,572 | (36,043 | ) | ||||
Net change in cash and restricted cash | 381 | (51,012 | ) | ||||
Cash and restricted cash at beginning of period | 9,713 | 65,946 | |||||
Cash and restricted cash at end of period | $ | 10,094 | $ | 14,934 | |||
Supplemental disclosure of cash flow information: | |||||||
Interest paid | $ | 45 | $ | 1,978 | |||
Income taxes (refunded) paid, net | (69 | ) | 130 | ||||
Non-cash financing and investing activities: | |||||||
Warrants issued in connection with Keep Well Notes (in 2023)/2024 Notes (in 2022) | $ | 10,797 | $ | 458 | |||
Finance lease and accrued purchases of property and equipment | 28 | 77 | |||||
Common stock issued to settle contingent consideration | — | 293 | |||||
Accrued debt issuance costs | 85 | 190 | |||||
ONTRAK, INC. | ||||||||||||||||
Reconciliation of Operating Loss to EBITDA and Adjusted EBITDA | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Operating loss | $ | (4,628 | ) | $ | (11,910 | ) | $ | (11,855 | ) | $ | (25,055 | ) | ||||
Depreciation expense | 295 | 773 | 590 | 1,424 | ||||||||||||
Amortization expense (1) | 351 | 410 | 742 | 805 | ||||||||||||
EBITDA | (3,982 | ) | (10,727 | ) | (10,523 | ) | (22,826 | ) | ||||||||
Stock-based compensation expense | 892 | 2,152 | 1,543 | 5,063 | ||||||||||||
Restructuring, severance and related costs (2) | — | — | 457 | — | ||||||||||||
Adjusted EBITDA | $ | (3,090 | ) | $ | (8,575 | ) | $ | (8,523 | ) | $ | (17,763 | ) | ||||
Reconciliation of Net Loss to Non-GAAP Net Loss; and Net Loss per Common Share to Non-GAAP Net Loss per Common Share | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net loss | $ | (6,756 | ) | $ | (15,058 | ) | $ | (15,106 | ) | $ | (29,703 | ) | ||||
Stock-based compensation expense | 892 | 2,152 | 1,543 | 5,063 | ||||||||||||
Write-off of debt issuance costs | — | 2,023 | — | 2,023 | ||||||||||||
Restructuring, severance and related costs (2) | — | — | 457 | — | ||||||||||||
Loss (gain) on change in fair value of warrant liability | (7 | ) | (51 | ) | 12 | (51 | ) | |||||||||
Gain on termination of operating lease (3) | — | — | (471 | ) | — | |||||||||||
Non-GAAP net loss | (5,871 | ) | (10,934 | ) | (13,565 | ) | (22,668 | ) | ||||||||
Dividends on preferred stock - declared and undeclared | (2,238 | ) | (2,238 | ) | (4,477 | ) | (4,477 | ) | ||||||||
Non-GAAP net loss attributable to common stockholders | $ | (8,109 | ) | $ | (13,172 | ) | $ | (18,042 | ) | $ | (27,145 | ) | ||||
Net loss per common share - basic and diluted | $ | (1.84 | ) | $ | (4.97 | ) | $ | (4.09 | ) | $ | (9.86 | ) | ||||
Non-GAAP net loss per common share - basic and diluted | (1.66 | ) | (3.78 | ) | (3.77 | ) | (7.83 | ) | ||||||||
Weighted-average common shares outstanding - basic and diluted | 4,887 | 3,481 | 4,787 | 3,468 | ||||||||||||
_______________________ | ||
(1) | Relates to operating and financing ROU assets and acquired intangible assets. | |
(2) | Includes one-time severance and related benefit costs related to a reduction in workforce announced in March 2023 as part of Company's continued cost savings measure. | |
(3) | Represents gain realized on derecognition of ROU operating asset and related lease liability due to early termination of the lease of the office space located in Santa Monica, CA in February 2023. | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809926366/en/
Contacts
For Investors:
Ryan Halsted
Gilmartin Group
investors@ontrakhealth.com
